Key Highlights

  • Co-Diagnostics (NASDAQ:CODX) quoted USD 0.4130 pre-market on Tuesday, November 10, 2026, up 29.47% from a calculated prior close of USD 0.3190 on Monday.
  • Published data showed a Market Value of USD 4.78 million on 6.25 million shares at USD 0.7645 on October 14, 2026, so the pre-market price is about 46% below that close (calculated).
  • Trailing 12-month Revenue was USD 721,386 against a net loss of USD 47.06 million, with cash of USD 3.65 million and total Debt of USD 1.80 million.
  • The 20-day average Volume was 359,681 shares and the 52-week price change was -93.38%, so the stock trades in a thin, deeply sold-down range.

What Moved Co-Diagnostics Pre-Market (+29.47%)

Co-Diagnostics is a Utah-based molecular diagnostics company listed on the Nasdaq. The pre-market snapshot on November 10, 2026 shows USD 0.4130, a gain of 29.47%. Simple arithmetic gives a calculated prior close of USD 0.3190, which means Monday's session ended roughly 58% below the October 14 close of USD 0.7645 (calculated). On the 6.25 million shares reported in published data, the pre-market price implies a market value of about USD 2.58 million (calculated), against USD 4.78 million at the October close. The 20-day average volume of 359,681 shares equals about USD 0.15 million of daily turnover at the pre-market price (calculated). The pre-market gain therefore follows a sharp fall, and a rebound from USD 0.3190 remains well under half of the October level. Investors should also note that a quote below USD 0.50 means each USD 0.01 tick is more than 2% of the price, so spreads look proportionally large and small orders move the print.

Rationale: No Catalyst Identified in Published Coverage

Searches turned up earnings-date notices for the third quarter of 2026 and filings on the SEC site, but no release dated November 9 or November 10, 2026 with results or deal terms. No catalyst is identified in published coverage. As general context, diagnostics small caps often move on quarterly results, grant or contract news, cash-runway updates, financing, or a Nasdaq minimum-bid notice, because a stock under USD 1.00 for 30 consecutive Business days can trigger a deficiency letter. A bounce after a steep decline also occurs without news when short sellers cover or buyers step into a thin book. None of this is confirmed for Co-Diagnostics (NASDAQ:CODX).

Valuation, Liquidity and Risks

At USD 0.4130, the shares trade below the USD 1.00 Nasdaq minimum-bid level, which raises the odds of a reverse split or a compliance process. Cash of USD 3.65 million against a trailing net loss of USD 47.06 million, which may include non-cash charges, points to a short runway unless funding is raised, and dilution would lower per-share value. Revenue of USD 721,386 is small next to the loss. The 52-week change of -93.38% shows how much value has been lost. Pre-market volume is thin, spreads are wide and the move can reverse at the open. Nothing here implies Co-Diagnostics (NASDAQ:CODX) will keep rising. Earnings, grant news and financing terms would each need to be read directly in the company filing before any conclusion is drawn about the next session or the balance sheet.

Where Things Stand

The most direct answer to why Co-Diagnostics (NASDAQ:CODX) is up 29.47% pre-market is that no catalyst was identified in published coverage. The USD 0.4130 quote sits on a calculated prior close of USD 0.3190 and below the October close of USD 0.7645. With USD 3.65 million in cash, a USD 47.06 million trailing loss and sub-USD 1.00 pricing, dilution and listing risk remain central.